HOME > TOP STORIES

TOP STORIES

REGULATORY New Plan Would Reduce Number of PMP-Eligible Products by 40-50%: MHLW Estimate

November 29, 2017
BUSINESS Tagrisso Filed for 1st-Line EGFR-Mutated NSCLC in Japan: AZ

November 28, 2017
ORGANIZATION PhRMA Japan Chief “Shocked” by Govt’s PMP Plan, Doesn’t Want It Institutionalized as Proposed

November 27, 2017
REGULATORY Draft Outline of Drug Pricing Overhaul Unveiled at Chuikyo; De-Facto Shrinkage for Price Maintenance Scheme Proposed

November 24, 2017
REGULATORY Chuikyo Agrees to Define Scope of Off-Year Re-Pricing by 2020-End for 1st Off-Year Revision in April 2021

November 22, 2017
TRENDS Large Gap in Performance of New Drugs; Products Including Clenafin, Uptravi Doing Well

November 22, 2017
BUSINESS Pfizer Begins Submitting Applications for Biosimilars, Could Be First Major New Drug Maker to Enter Japanese Market

November 21, 2017
REGULATORY Govt Plans to Apply 5 Price Bands for Listed Generics in “Off-Year” Revisions, Maintain 50% Rule for 1st Generics in April

November 20, 2017
REGULATORY Govt Plans Tiered PMP for Smaller Scope of Products, Post-Z2 Rule for LLPs

November 17, 2017
BUSINESS Transfer of LLPs from Chugai “Our Ticket to Admission” into Pharma Business: Taiyo Pharma COO

November 16, 2017
REGULATORY Chuikyo OKs Bavencio, Maviret, Ibrance and More for Listing on Nov. 22

November 15, 2017
ORGANIZATION Deeper Price Cuts Needed for Off-Patent Brands, Scrap 5-Year Grace Period: Chuikyo Payer Rep

November 14, 2017
REGULATORY Pilot CEA Program: Company Data, Third-Party Re-Analysis Data Show Big Gaps for Some Products

November 13, 2017
BUSINESS Can Japan’s 1st Enbrel Biosimilar Make Its Mark in RA Follow-On Arena with Self-Injection?

November 10, 2017
ACADEMIA In Renewed Attempt, Tokushima Univ. Starts IIT for Eisai-Dropped ALS Drug Candidate

November 9, 2017
COMMENTARY Unraveling MHLW/MOF Tug-of-War on Drug Pricing Reform

November 8, 2017
BUSINESS 4 Japan Drug Majors See Half-Year Profit Fall on One-Off Factors, but Global Flagships Thrive

November 7, 2017
ORGANIZATION Lower Price for Better Medicine? Limit Any CEA-Based Re-Pricing to Premium Portion, PhRMA Says

November 6, 2017
REGULATORY Payer Rep Calls on Govt to Promote Use of Formularies at Hospitals to Ensure Use of Cheaper Option: Chuikyo

November 2, 2017
REGULATORY PM Abe Watchful of Reward for Me-Too Drugs, CEFP Minutes Reveal

November 1, 2017

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

More Positions, More Candidates: A Snapshot of Movement in Japan’s Pharma Industry

By Philip Carrigan

Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…